93 related articles for article (PubMed ID: 12185379)
1. Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters.
Rosenbaum P; Peres RB; Zanella MT; Ferreira SR
Braz J Med Biol Res; 2002 Aug; 35(8):877-84. PubMed ID: 12185379
[TBL] [Abstract][Full Text] [Related]
2. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
[TBL] [Abstract][Full Text] [Related]
3. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.
Costa B; Piñol C
Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244
[TBL] [Abstract][Full Text] [Related]
4. Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus.
López-Alvarenga JC; Aguilar-Salinas CA; Velasco-Perez ML; Arita-Melzer O; Guillen LE; Wong B; Brito G; Mercado V; Gómez-Pérez FJ; Rull-Rodrigo JA
Diabetes Obes Metab; 1999 Jan; 1(1):29-35. PubMed ID: 11221809
[TBL] [Abstract][Full Text] [Related]
5. Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes.
Mughal MA; Memon MY; Zardari MK; Tanwani RK; Ali M
J Pak Med Assoc; 2000 May; 50(5):152-6. PubMed ID: 11242714
[TBL] [Abstract][Full Text] [Related]
6. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
[TBL] [Abstract][Full Text] [Related]
7. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects.
Ozata M; Gungor D; Turan M; Ozisik G; Bingol N; Ozgurtas T; Ozdemir IC
J Clin Endocrinol Metab; 2001 Aug; 86(8):3659-64. PubMed ID: 11502793
[TBL] [Abstract][Full Text] [Related]
8. Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment.
Calle-Pascual AL; Garcia-Honduvilla J; Martin-Alvarez PJ; Vara E; Calle JR; Munguira ME; Marañes JP
Diabete Metab; 1995 Oct; 21(4):256-60. PubMed ID: 8529760
[TBL] [Abstract][Full Text] [Related]
9. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes.
Hanefeld M; Haffner SM; Menschikowski M; Koehler C; Temelkova-Kurktschiev T; Wildbrett J; Fischer S
Diabetes Res Clin Pract; 2002 Mar; 55(3):221-7. PubMed ID: 11850098
[TBL] [Abstract][Full Text] [Related]
10. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
[TBL] [Abstract][Full Text] [Related]
11. Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients.
Güvener N; Gedik O
Acta Diabetol; 1999 Jun; 36(1-2):93-7. PubMed ID: 10436259
[TBL] [Abstract][Full Text] [Related]
12. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients.
Fischer S; Patzak A; Rietzsch H; Schwanebeck U; Köhler C; Wildbrett J; Fuecker K; Temelkova-Kurktschiev T; Hanefeld M
Diabetes Obes Metab; 2003 Jan; 5(1):38-44. PubMed ID: 12542723
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
Sieradzki J; Soszyński P
Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
[TBL] [Abstract][Full Text] [Related]
14. Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.
Inoue I; Takahashi K; Noji S; Awata T; Negishi K; Katayama S
Diabetes Res Clin Pract; 1997 Jun; 36(3):143-51. PubMed ID: 9237780
[TBL] [Abstract][Full Text] [Related]
15. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
16. The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: a randomized controlled study.
Rachmani R; Bar-Dayan Y; Ronen Z; Levi Z; Slavachevsky I; Ravid M
Diabetes Obes Metab; 2004 Jan; 6(1):63-8. PubMed ID: 14686965
[TBL] [Abstract][Full Text] [Related]
17. Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy.
Standl E; Baumgartl HJ; Füchtenbusch M; Stemplinger J
Diabetes Obes Metab; 1999 Jul; 1(4):215-20. PubMed ID: 11228756
[TBL] [Abstract][Full Text] [Related]
18. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus.
Göke B;
Treat Endocrinol; 2002; 1(5):329-36. PubMed ID: 15832486
[TBL] [Abstract][Full Text] [Related]
19. Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus?
Scott R; Lintott CJ; Zimmet P; Campbell L; Bowen K; Welborn T
Diabetes Res Clin Pract; 1999 Mar; 43(3):179-85. PubMed ID: 10369427
[TBL] [Abstract][Full Text] [Related]
20. Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study.
Willms B; Ruge D
Diabet Med; 1999 Sep; 16(9):755-61. PubMed ID: 10510952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
